Disa’s subsidiary Digital Life Line (DLL) is set to deploy its automated visual acuity test (AVAT) devices at a public hospital’s ophthalmology clinic in Singapore, reported The Edge Singapore.
The initiative comes after the receipt of a letter of award from the hospital.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The acknowledgement letter and related contract have been signed by DLL to deploy the devices from 3 February 2025 to 2 February 2026.
This deployment marks the first commercial use of the devices in the country, following Class A Medical Device Registration in August 2023 by the Health Science Authority (HSA) Singapore.
Under the contract, the company will provide the AVAT devices on a leasing arrangement. The pricing structure combines a fixed monthly rent with a per-test fee, ensuring a consistent revenue stream and scalability depending on usage.
DLL CEO and managing director Eddie Chng said: “We know that loss of eyesight is irreversible, so the widespread deployment of devices like AVAT in the community is key not only for early diagnosis and intervention but also to alleviate the workload at tertiary hospitals facing severe manpower shortages.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe initiative follows a pilot study for two months at a public hospital’s ophthalmology department, which evaluated the device’s accuracy, patient satisfaction and usability.
AVAT is developed through research by the Department of Ophthalmology at the National University Hospital in collaboration with the Centre for Innovation and Precision Eye Health at the Yong Loo Lin School of Medicine, National University of Singapore.
The ‘self-automated’ nature of the device enables testing which can be self-administered, eliminating the need for supervision.
It also claims to ‘decentralise’ eye screening and disease monitoring, offering an accessible and streamlined solution for visual acuity testing.
